Milciclib maleate

N/A

Report date: 2023/01/03 20:00:35
NME

Base Information

Drug NameMilciclib maleate
Drug Alias Name嘧西利milciclib米尔西利PHA-848125CPHA-848125 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsCyclin-dependent kinase 2 inhibitors
TargetsNerve growth factor receptor Trk-ACyclin-dependent kinase 2
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyFrance +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTiziana Life Sciences PlcNerviano Medical Sciences Srl
China Registration ClassN/A

Develop Information

Active CompaniesTiziana Life Sciences Ltd
Inactive CompaniesNerviano Medical Sciences Srl
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsSolid tumoursCarcinoma, HepatocellularThymoma

Other Information

ATC CodeN/A
Related LinksN/A